

26 August 2020

ASX Announcement

Blackmores Limited (BKL)

Correction to 2020 Annual Report

Blackmores Limited ("Blackmores") wishes to advise shareholders of a correction to the Note 2.2.1 Revenue by segment appearing on page 87 of the 2020 Annual Report released to the ASX 25 August 2020.

The correction relates to a disclosure note of revenue which should be \$109,774 rather than \$145,978. The correction has been reflected below.

2.2.1 Revenue by segment

	2020 \$'000	2019 \$'000
ANZ	227,369	266,989
China	102,933	122,249
BioCeuticals Group ¹	98,924	92,315
International	139,127	107,361
	568,353	588,914

1. BioCeuticals Group has been adjusted to exclude Global Therapeutics which is classified as a discontinued operation.

The Group has one customer who contributed more than 10% of the Group's revenue in the year (2019: One).

Included in revenue of the Group is revenue of \$109,774 (2019: \$143,873) which arose from sales to the Group's largest customer. This customer is within both the ANZ and BioCeuticals Group segments.

The correction does not impact on any other information in the Annual Report.

The Directors do not believe that the correction is material to the users and have not reissued the Consolidated Financial Statements in the Annual Report.

This will be corrected in the equivalent Note of the 2021 Annual Report.

For further information, please contact:

MEDIA CONTACT

Raffaele D'Alisa
Head of Strategic Communications
M +61 435 504 017

INVESTOR CONTACT

Michelle Gough
Group Financial Controller and Investor Relations
Manager
M +61 466 398 983